Acadian Asset Management
ABVX

Acadian Asset Management’s Abivax ABVX Stock Holding History

Acadian Asset Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,608
Closed -$1.41M – 1942
2025
Q3 		$1.41M Buy
+16,608
New +$1.02M ﹤0.01% 971

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Acadian Asset Management's ABVX Position: Q4 2025 in Review

Acadian Asset Management sold out of Abivax (ABVX) in Q4 2025, closing a stake of 16,608 shares — an estimated $1.41M sold.

Acadian Asset Management first reported a position in ABVX in Q3 2025 and held it in 1 quarter. The position peaked at $1.41M in Q3 2025. 247 funds tracked by Wall St. Rank hold ABVX as of Q4 2025.

  • Acadian Asset Management reported no remaining Abivax position as of Q4 2025 after selling out during the quarter.
  • Acadian Asset Management sold 16,608 Abivax shares in Q4 2025, an estimated $1.41M.
  • Acadian Asset Management first reported a position in Abivax in Q3 2025 and held it in 1 quarter.
  • Acadian Asset Management's Abivax position peaked at $1.41M in Q3 2025.
  • 247 funds tracked by Wall St. Rank held Abivax as of Q4 2025.

Based on Acadian Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.